US4140754A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hemagglutination-inhibition test for togaviruses
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1976-11-08
•
Granted: 1979-02-20
•
Expires: 1996-11-08
Abstract
Abstract The non-specific inhibitors of hemagglutination in a subject serum for hemagglutination-inhibition test for a togavirus such as rubella virus can be inactivated by subjecting the subject serum to the action of phospholipase C. By subjecting thus-treated serum to the hemagglutination-inhibition test employing fixed erythrocytes the togavirus hemagglutination-inhibition antibody titer of the serum can be determined accurately and with high sensitivity.
Inventors
- 👤 Susumu Iwasa
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 00:50
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/34; C12Q1/44; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56983; G01N2333/00; G01N2333/005; G01N2333/08; G01N2333/18; G01N2333/90; G01N2333/914; G01N2333/916; Y; Y02; Y02A; Y02A50/00; Y02A50/30; Y10; Y10S; Y10S436/00; Y10S436/826; Y10T; Y10T436/00; Y10T436/10; Y10T436/101666; Y10T436/107497; Y10T436/108331
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
91 words
In a hemagglutination-inhibition test for a togavirus which comprises inactivating the non-specific inhibitors of hemagglutination occurring in a subject serum, mixing the subject serum with a togavirus-specific hemagglutinating antigen and then with erythrocytes to assess occurrence of hemagglutination, the improvement comprising (1) preparing the subject serum for testing by contacting said serum with a solution containing about 0.04 to 0.12 units/ml of phospholipase C in an aqueous solvent for a time sufficient to inactivate the nonspecific inhibitors before the mixing with the antigen, and (2) employing fixed erythrocytes as the erythrocytes.
Claim 2
Dependent Claim
91 words
In a hemagglutination-inhibition test for a togavirus which comprises inactivating the non-specific inhibitors of hemagglutination occurring in a subject serum, mixing the subject serum with a togavirus-specific hemagglutinating antigen and then with erythrocytes to assess occurrence of hemagglutination, the improvement comprising (1) preparing the subject serum for testing by contacting said serum with a solution containing about 0.04 to 0.12 units/ml of phospholipase C in an aqueous solvent for a time sufficient to inactivate the nonspecific inhibitors before the mixing with the antigen, and (2) employing fixed erythrocytes as the erythrocytes.
Claim 3
Dependent Claim
25 words
The method according to claim 1, wherein the subject serum is contacted with phospholipase C at about 37° C. for about 3 to 20 hours.
Claim 4
Dependent Claim
13 words
The method according to claim 1, wherein the fixed erythrocytes are formalinized erythrocytes.
Claim 5
Dependent Claim
12 words
The method according to claim 1, wherein the togavirus is rubella virus.
Claim 6
Dependent Claim
18 words
The method according to claim 1, wherein the phospholipase C solution contains about 0.06 unit/ml of phospholipase C.
Claim 7
Dependent Claim
15 words
The method according to claim 1, wherein the subject serum is of warm-blooded animal origin.
Claim 8
Dependent Claim
12 words
The method according to claim 6, wherein the warm-blooded animal is human.
Claim 9
Dependent Claim
26 words
The method according to claim 1, wherein the subject serum is contacted with phospholipase C at a temperature between about 10° C. and about 50° C.
Claim 10
Dependent Claim
32 words
The method according to claim 8, further comprising incubating the mixture of serum and phospholipase C at 56° C. for 30 minutes after said contacting at about 10° to about 50° C.
Claim 11
Dependent Claim
15 words
The method according to claim 1, wherein the fixed erythrocytes are of warm-blooded animal origin.
Claim 12
Dependent Claim
12 words
The method according to claim 10, wherein the warm-blooded animal is fowl.
Claim 13
Dependent Claim
11 words
The method according to claim 11, wherein the fowl is chick.
Claim 14
Dependent Claim
26 words
The method according to claim 1, wherein said serum is diluted with a diluent selected from the group consisting of HEPES-Saline-Albumin-Gelatin, Veronal-Buffered Saline and Phosphate-Buffered Saline.
Claim 15
Dependent Claim
11 words
The method according to claim 13, wherein said diluent is HEPES-Saline-Albumin-Gelatin.
Claim 16
Dependent Claim
18 words
The method according to claim 13, further comprising serially diluting the serum in two-fold steps using said diluent.
References Cited (Backward Citations)
JPS4826913A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-02-19 | 1982-08-21 | 1983-02-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-02-19 | 1986-08-21 | 1987-02-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-02-19 | 1990-08-21 | 1991-02-20 | $7700.00 | Window Closed / Lapsed |